Multi-gene assay profiling testing in ER+/HER2- breast cancer: ASCO guidelinesinterpretation and Ruijin Hospital experience

doi:10.16139/j.1007-9610.2022.05.008

Abstract

CLC Number:

R737.9

SHU Lan, CHEN Xiaosong. Multi-gene assay profiling testing in ER+/HER2- breast cancer: ASCO guidelinesinterpretation and Ruijin Hospital experience[J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 416-420.

Figures/Tables 2

References 21

[1]	陈小松, 沈坤炜. 乳腺癌多基因阵列表达谱检测与个体化治疗[J]. 中华外科杂志, 2017, 55(2):99-103.
[2]	Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2016, 34(10):1134-1150.
[3]	Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update[J]. J Clin Oncol, 2017, 35(24):2838-2847.
[4]	Andre F, Ismaila N, Henry NL, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update—integration of results from TAILORx[J]. J Clin Oncol, 2019, 37(22):1956-1964.
[5]	Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update[J]. J Clin Oncol, 2022, 40(16):1816-1837.
[6]	陈小松, 沈坤炜. 多基因阵列表达谱检测在乳腺癌中的应用[J]. 外科理论与实践, 2019, 24(5):412-416.
[7]	Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. N Engl J Med, 2004, 351(27):2817-2826.
[8]	陈小松, 陈舒婕, 沈坤炜. 乳腺癌的分子分型[J]. 中华肿瘤杂志, 2008, 30(9):641-643.
[9]	Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med, 2018, 379(2):111-121.
[10]	Cardoso F, van′t Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med, 2016, 375(8):717-729.
[11]	Sapino A, Roepman P, Linn S, et al. MammaPrint mole-cular diagnostics on formalin-fixed, paraffin-embedded tissue[J]. J Mol Diagn, 2014, 16(2):190-197.
[12]	Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer[J]. N Engl J Med, 2015, 373(21):2005-2014.
[13]	Wu J, Fang Y, Lin L, et al. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients[J]. Oncotarget, 2017, 8(24):38706-38716.
[14]	Yu J, Wu J, Huang O, et al. Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30[J]. Oncol Lett, 2020, 20(2):1545-1556.
[15]	Yu J, Wu J, Huang O, et al. Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer[J]. Am J Cancer Res, 2021, 11(12):6188-6199.
[16]	Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer[J]. N Engl J Med, 2019, 380(25):2395-2405.
[17]	Sparano JA, Gray RJ, Makower DF, et al. Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial[J]. JAMA Oncol, 2020, 6(3):367-374.
[18]	Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer[J]. N Engl J Med, 2021, 385(25):2336-2347.
[19]	Tong Y, Wu J, Huang O, et al. 21-Gene recurrence score and adjuvant chemotherapy decision for breast cancer patients with positive lymph nodes[J]. Sci Rep, 2019, 9(1):13123.
[20]	Piccart M, van′t Veer LJ, Poncet C, et al. 70-Gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age[J]. Lancet Oncol, 2021, 22(4):476-488.
[21]	Tsai M, Lo S, Audeh W, et al. Association of 70-gene signature assay findings with physicians′ treatment gui-dance for patients with early breast cancer classified as intermediate risk by the 21-gene assay[J]. JAMA Oncol, 2018, 4(1):e173470.

组织学分级	淋巴结分期	肿瘤直径（cm）	MINDACT临床危险度分级
分化较好	pN₀	≤3	临床低危
	pN₀	3.1~5	临床高危
	pN₁	≤2	临床低危
	pN₁	2.1~5	临床高危
中度分化	pN₀	≤2	临床低危
	pN₀	2.1~5	临床高危
	pN₁	任何	临床高危
分化较差	pN₀	≤1	临床低危
	pN₀	1.1~5	临床高危
	pN₁	任何	临床高危

Multi-gene assay profiling testing in ER+/HER2- breast cancer: ASCO guidelinesinterpretation and Ruijin Hospital experience

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 21

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHU Qiaoli, MIAO Yiming, CHEN Xiaosong. Prognostic analysis of breast-conserving surgery or mastectomy in patients with stage Ⅰ-Ⅲ triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 371-377.
[2]	YANG Yi, YANG Xingxia, JIN Sili, ZHANG Xu, ZHU Juanying, CHEN Xiaosong. Clinical application of preoperative MRI examination in breast-conserving surgery for ductal carcinoma in situ [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 378-382.
[3]	DONG Jun, CUI Fengming, LIU Jun. Effects of silencing Ki-67 gene on doxorubicin resistance of breast cancer MCF-7/DOX cells [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 254-259.
[4]	GAO Weiqi, ZHANG Xu, WANG Zheng, ZHU Yifei, HUANG Jiahui, HONG Jin, ZHU Siji, CHEN Xiaosong, HUANG Ou, HE Jianrong, CHEN Weiguo, LI Yafen, SHEN Kunwei, XU Hua, WU Jiayi. Safety analysis of immediate breast reconstruction with deep inferior epigastric perforator after neoadjuvant treatment [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 147-151.
[5]	HUANG Wei, Ll Hengyu, DING Xiaoyi. Value and application of intervention in advanced breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 411-415.
[6]	CAO Lu, ZHENG Siyue, CHEN Jiayi. Management of regional lymph nodes in early-stage breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 406-410.
[7]	ZHOU Wenbin, TANG Xinyu, WANG Shui. Application of local microwave ablation in treatment of breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 403-405.
[8]	XIE Yanyan, LU Qing, DU Zhenggui. Endoscopic and robotic breast surgery: present and future—the experience of West China Hospital [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 396-402.
[9]	CHEN Yiding, WU Shijie. Surgical treatment of hereditary breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 392-395.
[10]	WU Jiayi, LU Yujie, HE Jinguang, SHEN Kunwei, XU Hua. Post-mastectomy implant-based breast reconstruction [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 387-391.
[11]	CHEN Xiaosong, SHEN Kunwei, Ll Hongwei. Diagnosis and treatment in early operable breast cancer: current status and prospect [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 385-386.
[12]	YANG Cuiyan, WANG Haoyu, CHEN Xiaosong, SHEN Kunwei. Study on tumour suppressor gene TP53 mutation and prognosis in patients with triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 421-428.
[13]	PAN Ruixin, CHEN Xiaosong, SHEN Kunwei. Study on circulating tumor DNA and circulating tumor cell detecting minimal residual disease in breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 463-467.
[14]	ZHU Siyi, CHEN Xiaosong, SHEN Kunwei. Study on obesity associated with prognosis of early breast cancer and efficacy of adjuvant therapy [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 468-472.
[15]	WANG Jieqiang, MA Dekui. Study on trophoblast cell-surface antigen 2 gene and triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 473-477.